Public Summary

Summary for ARTG Entry: 232957

Inverness Medical Innovations Australia Pty Ltd T/A Alere - Determine HIV-1/2 Ag/Ab Combo - HIV1/HIV2 antigen/antibody IVD, kit, immunochromatographic test (ICT), rapid

ARTG entry for
Medical Device Included - IVD Class 4

Sponsor
Inverness Medical Innovations Australia Pty Ltd T/A Alere

Postal Address
PO BOX 7063, East Brisbane, QLD, 4169

ARTG Start Date
20/01/2015

Product category
Medical Device Class 4

Status
Active

Approval area
IVD

Manufacturers

Name
Alere Medical Co Ltd

Address
357 Matsuhidai Matsudo-shi
, Chiba-ken, 270-2214
Japan

Products

1. Determine HIV-1/2 Ag/Ab Combo - HIV1/HIV2 antigen/antibody IVD, kit, immunochromatographic test (ICT), rapid

Product Type
IVD

Effective date
20/01/2015

GMDN
48447 HIV1/HIV2 antigen/antibody IVD, kit, immunochromatographic test (ICT), rapid

Functional description
The Determine HIV-1/2 Ag/Ab Combo is an immunochromatographic test for the qualitative detection of p24 antigen and antibodies to HIV-1 and HIV-2.

Intended purpose
The Determine HIV-1/2 Ag/Ab Combo is an In Vitro, visually read, qualitative immunoassay for the simultaneous detection of free non immunocomplexed HIV-1 p24 antigen (Ag) and antibodies (Ab) to HIV-1 and HIV-2 in human blood. The test specimen can be serum, plasma, fingerstick or venous whole blood. The test is intended as an aid to detect HIV-1 p24 antigen and antibodies to HIV-1/HIV-2 from infected individuals.

Variant Information

Specific Conditions

1. The person (the sponsor) in relation to whom the Alere Determine HIV 1/2 Ag/Ab Combo (the Device) is included in the Australian Register of Therapeutic Goods (the ARTG) must ensure that the Device is only supplied for use by:
   a) laboratories that are accredited by the National Association of Testing Authorities (NATA) as medical testing laboratories and that participate in an HIV point of care quality assurance program, or
   b) organisations that
      i) employ health professionals who will perform, or supervise the performance of, HIV testing using the device, and
      ii) have an established relationship (in relation to the referral and testing of specimens) with a NATA accredited medical testing laboratory, and
      iii) participate in an HIV point of care quality assurance program, and
      iv) provide a declaration to the sponsor every 12 months that all personnel using the Device have received training in the delivery and administration of HIV point of care devices in accordance with the requirements of the National HIV Testing Policy.

2. The sponsor of the Device (Alere Determine HIV 1/2 Ag/Ab Combo) must make available training in the correct use of the Device and interpretation of results.

3. The sponsor must maintain records that demonstrate that the Device has been supplied in compliance with condition 1 and that it has complied with condition 2.

4. The sponsor must provide to the Post Market Surveillance Branch (PMSB) of the Therapeutic Goods Administration, a post market surveillance report for each period of six (6) months commencing on the date of inclusion of the Device in the ARTG identifying any adverse events, problems or complaints relating to the use or application of the Device. The first report must be provided at the end of eight (8) months from the date of inclusion of the Device in the ARTG and each six (6) months thereafter, for a period of three years.

5. The sponsor must provide to the TGA a report and documents for each period of twelve (12) months commencing on the date of inclusion of the Device in the ARTG. The first report must be provided at the end of fourteen (14) months from the date of inclusion of the Device on the ARTG and each twelve (12) months thereafter. Information about the distribution of the Device and evidence of compliance with the conditions of ARTG inclusion for that twelve months (the period) must be provided, including
   a) copies of the current NATA accreditation certificate for each laboratory to which the Device has been supplied during the period and documented evidence of participation of the laboratory in an HIV point of care quality assurance program
   b) in relation to each organisation that is not an accredited medical testing laboratory
      i) documented evidence of a relationship of the kind referred to in condition 1b. above with a NATA accredited laboratory, and
      ii) documented evidence of the participation by the organisation in an HIV point of care quality assurance program, and
   c) documented evidence that condition 2 has been complied with by the sponsor during the period, and
   d) documented evidence that each person using the Device during the period has satisfactorily completed training in the correct use of the Device and interpretation of results being evidence that
      i) identifies the name and qualifications of health professionals who use or supervise the use of the Device, the date of their training and provider of the training,
ii) identifies the names of all other users of the Device, the date of their training and provider of the training,

iii) lists the specific skills and knowledge evaluated in the training, and

e) declarations, including certificates or other evidence, that each person using the Device has received training in the delivery and administration of HIV point of care devices in accordance with the requirements of the National HIV Testing Policy.

6. Post-market reports must be sent to the PMSB at the following email address, postmarketdevices@tga.gov.au.